Source: Eur Respir J, 52 (4) 1801220; 10.1183/13993003.01220-2018
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Guy Meyer, Benjamin Besse, Hélène Doubre, Anaïs Charles-Nelson, Sandro Aquilanti, Armine Izadifar, Reza Azarian, Isabelle Monnet, Corinne Lamour, Renaud Descourt, Gérard Oliviero, Laurent Taillade, Christos Chouaid, Frederique Giraud, Pierre-Emmanuel Falcoz, Marie-Pierre Revel, Virginie Westeel, Adrien Dixmier, Jean Tredaniel, Stéphanie Dehette, Chantal Decroisette, Alain Prevost, Eric Pichon, Elizabeth Fabre, Jean-Charles Soria, Sylvie Friard, Jean-Baptiste Stern, Laurence Jabot, Georges Dennewald, Gérard Pavy, Patrick Petitpretz, Jean-Marc Tourani, Marco Alifano, Gilles Chatellier, Philippe Girard. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J, 52 (4) 1801220; 10.1183/13993003.01220-2018

Member's Comments

No comment yet.

Related content which might interest you: A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001 A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008 Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Multicentre phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited stage small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 394s Year: 2001 Comparing different initial doses of afatinib used as first-line treatment for patients with stage IV lung adenocarcinoma Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 A randomised phase III comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 The effects of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008 Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 A phase II trial of lipoplatin-gemcitabine in patients with advanced NSCLC: preliminary results Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Chemotherapy in small cell lung cancer Source: Eur Respir J 2001; 18: 1026-1043 Year: 2001